ReviewCNS oncology2015
Medulloblastoma development: tumor biology informs treatment decisions.
Review in CNS oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells.Oncogene · 2026Article
- PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.Journal of neuro-oncology · 2024Article
- Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.Acta neurochirurgica · 2024Article
- OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- REST promotes ETS1-dependent vascular growth in medulloblastoma.Molecular oncology · 2021Article
- Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes.Bioinformatics (Oxford, England) · 2019Article
- Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.Gene · 2019Article
- Adult hemispheric cerebellar medulloblastoma.Surgical neurology international · 2018Article
- Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation.Oncotarget · 2017Article
- MPS1 kinase as a potential therapeutic target in medulloblastoma.Oncology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Medulloblastoma is the most common malignant pediatric brain tumor. Current treatments including surgery, craniospinal radiation and high-dose chemotherapy have led to improvement in survival. However, the risk for recurrence as well as significant long-term neurocognitive and endocrine sequelae associated with current treatment modalities underscore the urgent need for novel tumor-specific, normal brain-sparing therapies. It has also provided the impetus for research focused on providing a better understanding of medulloblastoma biology. The expectation is that such studies will lead to the identification of new therapeutic targets and eventually to an increase in personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.